The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20191479: Letterone Investment Holdings S.A.; ICG Europe Fund V No. 1 LP
20191480: Warburg Pincus Global Growth, L.P.; Olympus Growth Fund V, L.P.
1906001 Informal Interpretation
20191423: KPS Special Situations Fund IV, LP; Colfax Corporation
1906007 Informal Interpretation
1906011 Informal Interpretation
20191411: Trilantic Capital Partners VI (North America) L.P.; Oaktree Power Opportunities Fund III, L.P.
20191415: Milliken & Company; Versa Capital Fund I, L.P.
1906010 Informal Interpretation
20191406: Thoma Bravo Discover Fund II Global L.P.; Wells Fargo & Company
20191409: FirstService Corporation; Delos Investment Fund, L.P.
20191416: Vista Equity Partners Fund VII-A, L.P.; Trident VI, L.P.
20191426: Wells Fargo & Company; Mark S. Moussa
1906004 Informal Interpretation
Cure Encapsulations, Inc.
The FTC today announced its first case challenging a marketer’s use of fake paid reviews on an independent retail website. In settling the agency’s complaint, Cure Encapsulations, Inc. and its owner, Naftula Jacobowitz, resolved allegations that they made false and unsubstantiated claims for their garcinia cambogia weight-loss supplement and that they paid a third-party website to write and post fake reviews on Amazon.com.